Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback